Podcasts/Latham & Watkins/Connected With Latham
Episode 107 – Drug Pricing and Market Access: "Think of It as a Loop" — Succeeding in an Evolving Policy Landscape
Connected With Latham•byLatham & Watkins

Episode 107 – Drug Pricing and Market Access: "Think of It as a Loop" — Succeeding in an Evolving Policy Landscape

0:000:00
The pharmaceutical industry has seen major legal and policy changes in recent years, from the Inflation Reduction Act to the Trump administration's aggressive pricing policies. In this episode of Connected With Latham, Mike Domanico, a pharmaceutical industry veteran with experience in Big 4, brand drugs, biosimilars, and generics, and most recently Vice President of Revenue Finance, joins Washington, D.C. partner Chris Schott and associate Danny Machado to discuss how organizations can best respond to the changing environment. As Mike explains, think of meeting the challenge as a loop that connects the business, compliance, and legal in a cross-functional collaboration. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox. This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200
🏢 Latham & Watkins•107 Episodes•0 Subscribers•0 Total Listens

Episode Playlist

25 Episodes
Episode 107 – Drug Pricing and Market Access: "Think of It as a Loop" — Succeeding in an Evolving Policy Landscape
Dec 16, 2025•—

Episode 107 – Drug Pricing and Market Access: "Think of It as a Loop" — Succeeding in an Evolving Policy Landscape

Episode 106 – The FDA's New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway
Dec 15, 2025•—

Episode 106 – The FDA's New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway

Episode 105 – Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits
Nov 24, 2025•—

Episode 105 – Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits

Episode 104 – Drug Pricing and Market Access: Deep Dive on the FDA Commissioner's National Priority Voucher Program Awards
Nov 3, 2025•—

Episode 104 – Drug Pricing and Market Access: Deep Dive on the FDA Commissioner's National Priority Voucher Program Awards

Episode 103 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
Oct 2, 2025•—

Episode 103 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

Episode 102 – EU Data Act: Spotlight on Switching Requirements for Data Processing Services
Sep 11, 2025•—

Episode 102 – EU Data Act: Spotlight on Switching Requirements for Data Processing Services

Episode 101 – EU Data Act: Implications for Data Privacy and Cybersecurity
Sep 10, 2025•—

Episode 101 – EU Data Act: Implications for Data Privacy and Cybersecurity

Episode 100 – The Leeds Reforms: Implications for UK Financial Services
Jul 17, 2025•—

Episode 100 – The Leeds Reforms: Implications for UK Financial Services

Episode 99 – Drug Pricing: Takeaways from the Philadelphia Pricing and Contracting USA Conference
Jun 24, 2025•—

Episode 99 – Drug Pricing: Takeaways from the Philadelphia Pricing and Contracting USA Conference

Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting
Jun 6, 2025•—

Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting

Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation
May 2, 2025•—

Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation

Episode 96 – The Growth Rocketship: Shield AI's Takeoff Shows What's Possible in Defensetech
Apr 30, 2025•—

Episode 96 – The Growth Rocketship: Shield AI's Takeoff Shows What's Possible in Defensetech

Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE
Mar 12, 2025•—

Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE

Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
Feb 25, 2025•—

Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook

Episode 93 – EU's Digital Operational Resilience Act: What You Should Know and How to Stay Compliant
Jan 16, 2025•—

Episode 93 – EU's Digital Operational Resilience Act: What You Should Know and How to Stay Compliant

Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends
Jan 6, 2025•—

Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends

Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets
Jan 6, 2025•—

Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets

Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets
Jan 6, 2025•—

Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets

Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next?
Dec 30, 2024•—

Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next?

Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
Dec 16, 2024•—

Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?

Episode 87 – Drug Pricing: What's In the New CMS Medicaid Final Rule?
Nov 25, 2024•—

Episode 87 – Drug Pricing: What's In the New CMS Medicaid Final Rule?

Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
Oct 18, 2024•—

Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
Sep 18, 2024•—

Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Episode 84 – Pro Bono: Shabir Kabiri's Remarkable Journey from Afghanistan to Asylum in the US
Aug 20, 2024•—

Episode 84 – Pro Bono: Shabir Kabiri's Remarkable Journey from Afghanistan to Asylum in the US

Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?
Aug 19, 2024•—

Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?

Może ci się też spodobać